These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 21814507)

  • 1. Proteins with complex architecture as potential targets for drug design: a case study of Mycobacterium tuberculosis.
    Mészáros B; Tóth J; Vértessy BG; Dosztányi Z; Simon I
    PLoS Comput Biol; 2011 Jul; 7(7):e1002118. PubMed ID: 21814507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution and expansion of the Mycobacterium tuberculosis PE and PPE multigene families and their association with the duplication of the ESAT-6 (esx) gene cluster regions.
    Gey van Pittius NC; Sampson SL; Lee H; Kim Y; van Helden PD; Warren RM
    BMC Evol Biol; 2006 Nov; 6():95. PubMed ID: 17105670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. targetTB: a target identification pipeline for Mycobacterium tuberculosis through an interactome, reactome and genome-scale structural analysis.
    Raman K; Yeturu K; Chandra N
    BMC Syst Biol; 2008 Dec; 2():109. PubMed ID: 19099550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and characterization of potential druggable targets among hypothetical proteins of extensively drug resistant Mycobacterium tuberculosis (XDR KZN 605) through subtractive genomics approach.
    Uddin R; Siddiqui QN; Azam SS; Saima B; Wadood A
    Eur J Pharm Sci; 2018 Mar; 114():13-23. PubMed ID: 29174549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PGRS Domain of Rv0297 of
    Sharma T; Singh J; Grover S; P M; Firdos F; Alam A; Ehtesham NZ; Hasnain SE
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502303
    [No Abstract]   [Full Text] [Related]  

  • 6. Protein targets for structure-based anti-Mycobacterium tuberculosis drug discovery.
    Lou Z; Zhang X
    Protein Cell; 2010 May; 1(5):435-42. PubMed ID: 21203958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteome-wide subtractive approach to prioritize a hypothetical protein of XDR-Mycobacterium tuberculosis as potential drug target.
    Uddin R; Siddiqui QN; Sufian M; Azam SS; Wadood A
    Genes Genomics; 2019 Nov; 41(11):1281-1292. PubMed ID: 31388979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PE_PGRS proteins of
    De Maio F; Berisio R; Manganelli R; Delogu G
    Virulence; 2020 Dec; 11(1):898-915. PubMed ID: 32713249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Silico Drug Target Discovery Through Proteome Mining from M. tuberculosis: An Insight into Antivirulent Therapy.
    Bhattacharya S; Ghosh P; Banerjee D; Banerjee A; Ray S
    Comb Chem High Throughput Screen; 2020; 23(3):253-268. PubMed ID: 32072892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative analysis of Mycobacterium tuberculosis pe and ppe genes reveals high sequence variation and an apparent absence of selective constraints.
    McEvoy CR; Cloete R; Müller B; Schürch AC; van Helden PD; Gagneux S; Warren RM; Gey van Pittius NC
    PLoS One; 2012; 7(4):e30593. PubMed ID: 22496726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Proteomic Analysis of Aminoglycosides Resistant and Susceptible Mycobacterium tuberculosis Clinical Isolates for Exploring Potential Drug Targets.
    Sharma D; Kumar B; Lata M; Joshi B; Venkatesan K; Shukla S; Bisht D
    PLoS One; 2015; 10(10):e0139414. PubMed ID: 26436944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of a subtractive genomics approach for in silico identification and characterization of novel drug targets in Mycobacterium tuberculosis F11.
    Hosen MI; Tanmoy AM; Mahbuba DA; Salma U; Nazim M; Islam MT; Akhteruzzaman S
    Interdiscip Sci; 2014 Mar; 6(1):48-56. PubMed ID: 24464704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteome-wide lysine acetylation profiling of the human pathogen Mycobacterium tuberculosis.
    Xie L; Wang X; Zeng J; Zhou M; Duan X; Li Q; Zhang Z; Luo H; Pang L; Li W; Liao G; Yu X; Li Y; Huang H; Xie J
    Int J Biochem Cell Biol; 2015 Feb; 59():193-202. PubMed ID: 25456444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycobacterium tuberculosis: a model system for structural genomics.
    Smith CV; Sacchettini JC
    Curr Opin Struct Biol; 2003 Dec; 13(6):658-64. PubMed ID: 14675542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PknB remains an essential and a conserved target for drug development in susceptible and MDR strains of M. Tuberculosis.
    Gupta A; Pal SK; Pandey D; Fakir NA; Rathod S; Sinha D; SivaKumar S; Sinha P; Periera M; Balgam S; Sekar G; UmaDevi KR; Anupurba S; Nema V
    Ann Clin Microbiol Antimicrob; 2017 Aug; 16(1):56. PubMed ID: 28821299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of Certain Well-Characterized Domains of Known Functions within the PE and PPE Proteins of Mycobacteria.
    Sultana R; Tanneeru K; Kumar AB; Guruprasad L
    PLoS One; 2016; 11(2):e0146786. PubMed ID: 26891364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing the structural coverage of tuberculosis drug targets.
    Baugh L; Phan I; Begley DW; Clifton MC; Armour B; Dranow DM; Taylor BM; Muruthi MM; Abendroth J; Fairman JW; Fox D; Dieterich SH; Staker BL; Gardberg AS; Choi R; Hewitt SN; Napuli AJ; Myers J; Barrett LK; Zhang Y; Ferrell M; Mundt E; Thompkins K; Tran N; Lyons-Abbott S; Abramov A; Sekar A; Serbzhinskiy D; Lorimer D; Buchko GW; Stacy R; Stewart LJ; Edwards TE; Van Voorhis WC; Myler PJ
    Tuberculosis (Edinb); 2015 Mar; 95(2):142-8. PubMed ID: 25613812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the progress of Mycobacterium tuberculosis H37Rv structural genomics.
    Fang Z; van der Merwe RG; Warren RM; Schubert WD; Gey van Pittius NC
    Tuberculosis (Edinb); 2015 Mar; 95(2):131-6. PubMed ID: 25578513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single nucleotide variation catalog from clinical isolates mapped on tertiary and quaternary structures of ESX-1-related proteins reveals critical regions as putative Mtb therapeutic targets.
    Tzfadia O; Gijsbers A; Vujkovic A; Snobre J; Vargas R; Dewaele K; Meehan CJ; Farhat M; Hakke S; Peters PJ; de Jong BC; Siroy A; Ravelli RBG
    Microbiol Spectr; 2024 Aug; 12(8):e0381623. PubMed ID: 38874407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.